{
"id":"mk19_b_cv_s12",
"subspecialtyId":"cv",
"title":"Cardiovascular Disease in Cancer Survivors",
"jsonContent":{
"type":"section",
"id":"mk19_b_cv_s12",
"title":{
"__html":"Cardiovascular Disease in Cancer Survivors"
},
"titleNode":{
"type":"section-title",
"hlId":"9728d7",
"children":[
"Cardiovascular Disease in Cancer Survivors"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_cv_s12_1",
"title":{
"__html":"Cardiotoxicity of Radiation Therapy to the Thorax"
},
"titleNode":{
"type":"section-title",
"hlId":"bdc475",
"children":[
"Cardiotoxicity of Radiation Therapy to the Thorax"
]
},
"children":[
{
"type":"p",
"hlId":"3f0090",
"children":[
"Radiation therapy improves survival in patients with Hodgkin lymphoma, early-stage breast cancer, and other thoracic malignancies. With higher survival rates, cardiovascular disease has emerged as the most common nonmalignant cause of death in patients treated with chest radiation therapy, accounting for 25% of deaths in survivors of Hodgkin lymphoma."
]
},
{
"type":"p",
"hlId":"7ee369",
"children":[
"Radiation therapy causes a wide spectrum of cardiovascular diseases ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_cv_t42",
"wrapId":"1",
"children":[
"Table 42"
]
}
]
},
")"
]
},
". Thoracic irradiation damages all cells, including those of the pericardium, myocardium, valves, coronary and peripheral vasculature, and conduction system, with clinical disease usually presenting two to three decades after treatment. The risk for radiation-induced cardiac injury is increased further in patients taking concomitant anthracyclines or trastuzumab. Contemporary techniques that limit total dosage and field size have decreased the risk for cardiac complications following radiation therapy."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_cv_t42"
]
},
{
"type":"p",
"hlId":"6d0616",
"children":[
"Acute pericarditis is the most common early manifestation of radiotoxicity, affecting 2.5% of patients. The presentation, diagnosis, and treatment are similar to those of idiopathic acute pericarditis. Chronic or constrictive pericarditis develops in 10% to 20% of patients 5 to 10 years after radiation therapy. Pericardial calcification is not always present radiographically. Late constriction can occur in those who have not experienced acute pericarditis."
]
},
{
"type":"p",
"hlId":"fe8ba4",
"children":[
"Radiation also damages the microvasculature, causing endothelial dysfunction and ischemia that result in myocardial fibrosis, diastolic dysfunction, and restrictive physiology. Radiation-induced cardiomyopathy presents similarly to primary restrictive cardiomyopathy. Differentiating cardiomyopathy due to myocardial fibrosis from pericardial constriction is essential because the conditions have different treatments and outcomes (see ",
{
"type":"cross-reference",
"target":"mk19_b_cv_s7_3_1_1",
"children":[
"Myocardial Disease"
]
},
")."
]
},
{
"type":"p",
"hlId":"603e58",
"children":[
"Although all cardiac valves may be affected by radiation therapy, left-sided involvement predominates. Valvular regurgitation due to tissue retraction is the most common valvular lesion in the first two decades after therapy, with later fibrosis and calcification leading to mixed regurgitation and stenosis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_cv_f61",
"wrapId":"2",
"children":[
"Figure 61"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_cv_f61"
]
},
{
"type":"p",
"hlId":"87dfda",
"children":[
"Radiation causes fibrosis of the conduction system and may lead to sinus node dysfunction, fascicular and bundle branch blocks, and complete heart block. Up to 75% of long-term survivors of mediastinal radiation demonstrate conduction abnormalities on ECG. The need for permanent pacing is more common after valve replacement surgery in patients who have received radiation therapy."
]
},
{
"type":"p",
"hlId":"6bf801",
"children":[
"Coronary artery disease (CAD) occurs earlier and with increased incidence in patients treated with radiation therapy. Coronary artery lesions are typically ostial, long, smooth, and concentric and have higher fibrotic content than typical atherosclerotic lesions. The incidence of CAD is increased by traditional risk factors (e.g., smoking, dyslipidemia, and hypertension), and aggressive therapy to address these risk factors is indicated."
]
},
{
"type":"p",
"hlId":"bdddbd",
"children":[
"Surgical outcomes for patients with radiation-associated cardiovascular disease are significantly worse than in matched cohorts, and radiation-associated aortic stenosis is associated with worse short-term and long-term cardiovascular mortality. Recent trials have suggested that percutaneous approaches to aortic valve replacement may be preferable in this group."
]
},
{
"type":"p",
"hlId":"6b8c0f",
"children":[
"There is no consensus on cardiac testing after chest irradiation in asymptomatic patients. Baseline evaluation including echocardiography is reasonable, and several organizations have recommended stress echocardiography at 5 to 10 years after completion of therapy or at age 30 years, whichever comes first. The role of serum biomarkers in surveillance is unclear, and their use is not recommended. Routine screening with nuclear medicine testing or coronary CT should be avoided."
]
},
{
"type":"p",
"hlId":"815a04",
"children":[
"Statins, ACE inhibitors, and aldosterone antagonists, although effective for risk factor reduction, have not been proved to prevent radiation-induced cardiovascular disease."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e9c502",
"children":[
"Thoracic irradiation damages all cells, including those of the pericardium, myocardium, valves, coronary vasculature, and conduction system, with clinical disease usually presenting two to three decades after treatment."
]
},
{
"type":"keypoint",
"hlId":"42c70f",
"children":[
"In patients with a history of chest irradiation, traditional cardiovascular risk factors, such as smoking, dyslipidemia, and hypertension, should be aggressively managed because of the increased risk for coronary artery disease."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s12_2",
"title":{
"__html":"Cardiotoxicity of Chemotherapy"
},
"titleNode":{
"type":"section-title",
"hlId":"e17374",
"children":[
"Cardiotoxicity of Chemotherapy"
]
},
"children":[
{
"type":"p",
"hlId":"e76078",
"children":[
"Chemotherapy may cause reversible or dose-dependent, irreversible cardiac injury ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_cv_t43",
"wrapId":"3",
"children":[
"Table 43"
]
}
]
},
")"
]
},
". Strategies to minimize cardiovascular risk should be considered before initiation of chemotherapy, including optimizing treatment of traditional risk factors and identifying patients with the greatest long-term risk ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_cv_t44",
"wrapId":"3",
"children":[
"Table 44"
]
}
]
},
")"
]
},
". Cardiotoxic therapies should be minimized if there are alternative therapies with equivalent outcomes."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_cv_t43",
"mk19_b_cv_t44"
]
},
{
"type":"p",
"hlId":"251ce6",
"children":[
"Acute anthracycline toxicity, which can present as heart block, arrhythmias, heart failure, myocarditis, or pericarditis, occurs in fewer than 1% of patients and may be reversible. Chronic progressive anthracycline toxicity usually presents as dilated cardiomyopathy and is typically irreversible. It is most closely linked with doxorubicin but may occur with epirubicin and idarubicin. Chronic progressive toxicity has an early onset (within 1 year of treatment) in 1.6% to 2.1% of patients and a late onset (after 1 year) in up to 5% of patients. Late-onset chronic progressive toxicity is related to total cumulative dose. In patients with a cumulative anthracycline dose of 550 mg/m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
", the incidence of heart failure is up to 26%, and toxicity may not become clinically evident until 10 to 20 years after treatment. Dexrazoxane, an iron chelator, reduces the incidence of anthracycline cardiotoxicity and should be considered for those at increased risk. Continuous anthracycline administration, as opposed to bolus, and liposomal formulations of doxorubicin also should be considered to lower risk for anthracycline toxicity. The use of ACE inhibitors, angiotensin receptor blockers, and β-blockers to prevent cardiotoxicity is an ongoing area of interest, with conflicting results from small studies."
]
},
{
"type":"p",
"hlId":"8e4fbd",
"children":[
"Reversible injury is more commonly associated with targeted molecular therapy, such as trastuzumab, multitargeted tyrosine kinase inhibitors, and anti–vascular endothelial growth factor antibodies. Trastuzumab toxicity causes left ventricular (LV) systolic dysfunction, with symptoms of heart failure in 3% to 7% of patients. It is more common in patients older than 50 years and with concomitant anthracycline use. Multitargeted tyrosine kinase inhibitors also cause cardiotoxicity, although not all tyrosine kinase inhibitors carry the same risk. Sunitinib is associated with up to a 50% incidence of new or worsened hypertension and up to a 15% incidence of decreased LV ejection fraction (LVEF). These effects may be reversible with early recognition. Bevacizumab, an anti–vascular endothelial growth factor antibody, is associated with significant but reversible hypertension."
]
},
{
"type":"p",
"hlId":"a0aa7f",
"children":[
"In patients preparing to receive chemotherapy associated with possible LV dysfunction, baseline echocardiography is recommended. Measurement of global longitudinal strain (GLS) as part of surveillance echocardiography has been recommended by some expert consensus panels. GLS expresses longitudinal myocardial shortening as a simple percentage and may be more sensitive than other echocardiographic techniques in detecting early myocardial dysfunction. For patients in whom echocardiography is technically difficult, multigated acquisition and cardiac magnetic resonance imaging are alternatives."
]
},
{
"type":"p",
"hlId":"3759a6",
"children":[
"Although the frequency of surveillance of asymptomatic patients must be based on clinical judgment, it is reasonable to repeat echocardiography at a cumulative anthracycline dose of 250 mg/m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" and before each dose in patients with pre-existing LV dysfunction or those receiving higher cumulative doses. The frequency of echocardiographic surveillance in patients receiving trastuzumab who are at high risk for cardiac dysfunction is based on clinical judgment. Trastuzumab is temporarily stopped if the LVEF drops by more than 15% or drops 10% to 15% and below the normal level. Patients who demonstrate normalization of LV function after discontinuation of trastuzumab may receive additional therapy, and retrospective data has shown that patients whose LVEF remains greater than 50% may continue treatment without long-term cardiac effects. A relative decline in GLS of greater than 15% is considered subclinical LV dysfunction and should prompt consultation with a cardiologist. In patients taking sunitinib, surveillance with baseline N-terminal pro-B-type natriuretic peptide measurement and LVEF assessment at baseline, 1 month, and every 3 months thereafter has been advocated."
]
},
{
"type":"p",
"hlId":"ddcee4",
"children":[
"Echocardiography may be repeated at therapy completion and at 6 to 12 months in asymptomatic patients at increased risk. Currently, there are no guidelines for long-term surveillance of patients with normal LVEF after cardiotoxic chemotherapy."
]
},
{
"type":"p",
"hlId":"ba69ff",
"children":[
"In patients with clinical signs or symptoms of cardiac dysfunction, measurement of cardiac biomarkers (e.g., troponin, N-terminal pro–B-type natriuretic peptide) and echocardiography including GLS are recommended in identifying early toxicity and guiding individual therapy. At present, treatment of patients with chemotherapy-induced heart failure follows standard paradigms, and decisions regarding continuation of chemotherapy must be individualized."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2f014a",
"children":[
"Traditional cardiovascular risk factors increase the cardiotoxic risk of chemotherapy and should be managed aggressively."
]
},
{
"type":"keypoint",
"hlId":"a11f41",
"children":[
"Chronic anthracycline toxicity usually presents as irreversible dilated cardiomyopathy."
]
},
{
"type":"keypoint",
"hlId":"9781ff",
"children":[
"Cardiotoxicity from trastuzumab manifests as reversible left ventricular systolic dysfunction."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s12_3",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2017;13:270-275. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27922796",
"target":"_blank"
},
"children":[
"PMID: 27922796"
]
},
" doi:10.1200/JOP.2016.018770"
]
},
{
"type":"reference",
"children":[
"Donnellan E, Masri A, Johnston DR, et al. Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J Am Heart Assoc. 2017;6. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28476874",
"target":"_blank"
},
"children":[
"PMID: 28476874"
]
},
" doi:10.1161/JAHA.116.005396"
]
},
{
"type":"reference",
"children":[
"Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-53. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/15247354",
"target":"_blank"
},
"children":[
"PMID: 15247354"
]
}
]
},
{
"type":"reference",
"children":[
"Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-39. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25172399",
"target":"_blank"
},
"children":[
"PMID: 25172399"
]
},
" doi:10.1016/j.echo.2014.07.012"
]
},
{
"type":"reference",
"children":[
"Yang H, Wright L, Negishi T, et al. Research to practice: assessment of left ventricular global longitudinal strain for surveillance of cancer chemotherapeutic-related cardiac dysfunction. JACC Cardiovasc Imaging. 2018;11:1196-1201. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30092974",
"target":"_blank"
},
"children":[
"PMID: 30092974"
]
},
" doi:10.1016/j.jcmg.2018.07.005"
]
},
{
"type":"reference",
"children":[
"Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-47. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/19520246",
"target":"_blank"
},
"children":[
"PMID: 19520246"
]
},
" doi:10.1016/j.jacc.2009.02.050"
]
},
{
"type":"reference",
"children":[
"Yu AF, Yadav NU, Eaton AA, et al. Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Oncologist. 2015;20:1105-10. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26240135",
"target":"_blank"
},
"children":[
"PMID: 26240135"
]
},
" doi:10.1634/theoncologist.2015-0125"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_cv_t42":{
"id":"mk19_b_cv_t42",
"number":42,
"bookId":"cv",
"title":{
"__html":"Cardiovascular Diseases Related to Radiation Therapy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6fbd92",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 42. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_cv_t42"
}
]
},
"Cardiovascular Diseases Related to Radiation Therapy"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9d162",
"class":"cell txt l",
"children":[
"Cardiomyopathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba96ad",
"class":"cell txt l",
"children":[
"Conduction defects (atrioventricular block, bundle branch block)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75de70",
"class":"cell txt l",
"children":[
"Coronary artery disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0ade10",
"class":"cell txt l",
"children":[
"Coronary microvascular injury"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd0a7e",
"class":"cell txt l",
"children":[
"Pericardial disease (acute pericarditis, chronic constrictive pericarditis, pericardial effusion)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb58ad",
"class":"cell txt l",
"children":[
"Peripheral artery disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c7951",
"class":"cell txt l",
"children":[
"Valvular disease"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_cv_t43":{
"id":"mk19_b_cv_t43",
"number":43,
"bookId":"cv",
"title":{
"__html":"Cardiovascular Toxicities Associated with Chemotherapy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"fa3d5a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 43. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_cv_t43"
}
]
},
"Cardiovascular Toxicities Associated with Chemotherapy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"688250",
"class":"col hd l",
"children":[
"Toxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"626c25",
"class":"col hd l",
"children":[
"Drugs"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ebb614",
"class":"cell txt l",
"children":[
"Left ventricular dysfunction"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c2dd5",
"class":"cell txt l",
"children":[
"Alkylating agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"263ae5",
"class":"cell txt l",
"children":[
"Cyclophosphamide, ifosfamide"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea0fda",
"class":"cell txt l",
"children":[
"Anthracyclines"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"291988",
"class":"cell txt l",
"children":[
"Doxorubicin, epirubicin, idarubicin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f34af",
"class":"cell txt l",
"children":[
"Antimicrotubular agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"814873",
"class":"cell txt l",
"children":[
"Paclitaxel, docetaxel"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d6fd2",
"class":"cell txt l",
"children":[
"Monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c0c51",
"class":"cell txt l",
"children":[
"Trastuzumab"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"11208d",
"class":"cell txt l",
"children":[
"Proteasome inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c8a6ab",
"class":"cell txt l",
"children":[
"Bortezomib, carfilzomib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e864e9",
"class":"cell txt l",
"children":[
"Tyrosine kinase inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4b167",
"class":"cell txt l",
"children":[
"Sunitinib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"617b8b",
"class":"cell txt l",
"children":[
"Ischemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca2328",
"class":"cell txt l",
"children":[
"Antimetabolites"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a735b7",
"class":"cell txt l",
"children":[
"5-Fluorouracil, capecitabine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f34af",
"class":"cell txt l",
"children":[
"Antimicrotubular agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"814873",
"class":"cell txt l",
"children":[
"Paclitaxel, docetaxel"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d6fd2",
"class":"cell txt l",
"children":[
"Monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"54e253",
"class":"cell txt l",
"children":[
"Bevacizumab"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a9e74",
"class":"cell txt l",
"children":[
"Tyrosine kinase inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a5700",
"class":"cell txt l",
"children":[
"Erlotinib, sorafenib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01da3e",
"class":"cell txt l",
"children":[
"Hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d6fd2",
"class":"cell txt l",
"children":[
"Monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"54e253",
"class":"cell txt l",
"children":[
"Bevacizumab"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a9e74",
"class":"cell txt l",
"children":[
"Tyrosine kinase inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e2612",
"class":"cell txt l",
"children":[
"Sorafenib, sunitinib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f670bf",
"class":"cell txt l",
"children":[
"Venous thromboembolism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a8949",
"class":"cell txt l",
"children":[
"Alkylating agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8c898",
"class":"cell txt l",
"children":[
"Cisplatin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec4368",
"class":"cell txt l",
"children":[
"Angiogenesis inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"874d90",
"class":"cell txt l",
"children":[
"Thalidomide"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e864e9",
"class":"cell txt l",
"children":[
"Tyrosine kinase inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fadaee",
"class":"cell txt l",
"children":[
"Erlotinib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"919238",
"class":"cell txt l",
"children":[
"Bradycardia/atrioventricular block"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec4368",
"class":"cell txt l",
"children":[
"Angiogenesis inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"874d90",
"class":"cell txt l",
"children":[
"Thalidomide"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16a83d",
"class":"cell txt l",
"children":[
"Antimicrotubular agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fab09",
"class":"cell txt l",
"children":[
"Paclitaxel"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d2fc2",
"class":"cell txt l",
"children":[
"QT prolongation resulting in torsades de pointes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a8949",
"class":"cell txt l",
"children":[
"Alkylating agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e5d1d9",
"class":"cell txt l",
"children":[
"Oxaliplatin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c84d3",
"class":"cell txt l",
"children":[
"Anthracycline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6605d3",
"class":"cell txt l",
"children":[
"Aclarubicin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"387baf",
"class":"cell txt l",
"children":[
"Miscellaneous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b49d4",
"class":"cell txt l",
"children":[
"Arsenic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e864e9",
"class":"cell txt l",
"children":[
"Tyrosine kinase inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5869db",
"class":"cell txt l",
"children":[
"Vandetanib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2d4c1",
"class":"cell txt l",
"children":[
"Atrial fibrillation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c2dd5",
"class":"cell txt l",
"children":[
"Alkylating agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae9d39",
"class":"cell txt l",
"children":[
"Cisplatin, cyclophosphamide, ifosfamide"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea0fda",
"class":"cell txt l",
"children":[
"Anthracyclines"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"edab7d",
"class":"cell txt l",
"children":[
"Doxorubicin, aclacinomycin A, mitoxantrone"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca2328",
"class":"cell txt l",
"children":[
"Antimetabolites"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d03c6f",
"class":"cell txt l",
"children":[
"5-Fluorouracil, leucovorin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8751b0",
"class":"cell txt l",
"children":[
"Histone deacetylase inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ad873",
"class":"cell txt l",
"children":[
"Belinostat"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da79a9",
"class":"cell txt l",
"children":[
"Microtubule agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15508b",
"class":"cell txt l",
"children":[
"Paclitaxel, docetaxel, gemcitabine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6d107",
"class":"cell txt l",
"children":[
"Monoclonal antibodies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1311e3",
"class":"cell txt l",
"children":[
"Trastuzumab, etaracizumab"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a9e74",
"class":"cell txt l",
"children":[
"Tyrosine kinase inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c01045",
"class":"cell txt l",
"children":[
"Cetuximab, sunitinib, sorafenib, ibrutinib"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f58c83",
"class":"cell txt l",
"children":[
"Monomorphic ventricular tachycardia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea0fda",
"class":"cell txt l",
"children":[
"Anthracyclines"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e15fa8",
"class":"cell txt l",
"children":[
"Doxorubicin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7638b5",
"class":"cell txt l",
"children":[
"Antimetabolite"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05d087",
"class":"cell txt l",
"children":[
"5-Fluorouracil"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"387baf",
"class":"cell txt l",
"children":[
"Miscellaneous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b49d4",
"class":"cell txt l",
"children":[
"Arsenic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6d107",
"class":"cell txt l",
"children":[
"Monoclonal antibodies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13d91d",
"class":"cell txt l",
"children":[
"Nivolumab, trastuzumab"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Information from Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020;142:e214-e233. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32929996",
"target":"_blank"
},
"children":[
"PMID: 32929996"
]
},
" doi:10.1161/CIR.0000000000000905"
]
]
},
"mk19_b_cv_t44":{
"id":"mk19_b_cv_t44",
"number":44,
"bookId":"cv",
"title":{
"__html":"Cancer Therapy–Associated Factors That Increase Long-Term Cardiovascular Risk"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9e3990",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 44. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_cv_t44"
}
]
},
"Cancer Therapy–Associated Factors That Increase Long-Term Cardiovascular Risk"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb60f7",
"class":"cell txt l",
"children":[
"Anthracycline or trastuzumab in patients with multiple cardiovascular risk factors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0516fc",
"class":"cell txt l",
"children":[
"High-dose anthracycline (≥250 mg/m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" doxorubicin or ≥600 mg/m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" epirubicin)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a700f",
"class":"cell txt l",
"children":[
"Combination anthracycline and trastuzumab"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a75974",
"class":"cell txt l",
"children":[
"Combination anthracycline and radiation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4438fc",
"class":"cell txt l",
"children":[
"Radiation of ≥30 Gy with the heart in the treatment field"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}